Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Combined With Decitabine and/or Pralatrexate in PTCL and CTCL
NCT03240211Phase 1Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Feb 2022
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) (3 arms), sponsored by University of Virginia. Primary endpoints: Maximum Tolerated Dose, Dose Limiting Toxicity and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03240211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240211.